Cargando…

Effectiveness of Vortioxetine in Patients With Major Depressive Disorder in Real-World Clinical Practice: Results of the RELIEVE Study

BACKGROUND: Randomized controlled clinical trials have shown vortioxetine to be efficacious and well tolerated for the treatment of major depressive disorder (MDD). The Real-Life Effectiveness of Vortioxetine in Depression (RELIEVE) study was undertaken to demonstrate the effectiveness and safety of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mattingly, Gregory W., Ren, Hongye, Christensen, Michael Cronquist, Katzman, Martin A., Polosan, Mircea, Simonsen, Kenneth, Hammer-Helmich, Lene
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Psychiatry
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8959350/ https://www.ncbi.nlm.nih.gov/pubmed/35356713 http://dx.doi.org/10.3389/fpsyt.2022.824831

Ejemplares similares

Effectiveness of Vortioxetine in Patients with Major Depressive Disorder in Real-World Clinical Practice: French Cohort Results from the Global RELIEVE Study
por: Polosan, Mircea, et al.
Publicado: (2022)

Effectiveness of vortioxetine for major depressive disorder in real-world clinical practice: US cohort results from the global RELIEVE study
por: Mattingly, Gregory, et al.
Publicado: (2023)

Effectiveness of vortioxetine in real-world clinical practice: Interim results from the relieve study
por: Mattingly, G., et al.
Publicado: (2021)

Effectiveness of Vortioxetine in Patients with Major Depressive Disorder in Real-World Clinical Practice in Italy: Results from the RELIEVE Study
por: De Filippis, Sergio, et al.
Publicado: (2022)

Effectiveness and Safety of Vortioxetine for Major Depressive Disorder in Real-World Clinical Practice: Results from the Single-Arm RELIEVE China Study
por: Wang, Gang, et al.
Publicado: (2022)

Effectiveness of vortioxetine in real-world clinical practice: French cohort results from the global RELIEVE study
por: Polosan, M., et al.
Publicado: (2022)

Effectiveness of vortioxetine in patients with major depressive disorder and co-morbid generalized anxiety disorder in routine clinical practice: A subgroup analysis of the RELIEVE study
por: Almeida, Susana S, et al.
Publicado: (2022)

Efficacy of vortioxetine on the physical symptoms of major depressive disorder
por: Christensen, Michael Cronquist, et al.
Publicado: (2018)

Safety and effectiveness of vortioxetine for major depressive disorder: Real-world evidence from a population-based study in South Korea
por: Moon, Seok Woo, et al.
Publicado: (2023)

The Efficacy of Vortioxetine on Anhedonia in Patients With Major Depressive Disorder
por: Cao, Bing, et al.
Publicado: (2019)

Effectiveness of vortioxetine in real-world clinical practice: Italian cohort results from the global RELIEVE study
por: De Filippis, S., et al.
Publicado: (2022)

Gut Microbiota Changes in Patients With Major Depressive Disorder Treated With Vortioxetine
por: Ye, Xiaolin, et al.
Publicado: (2021)

Effectiveness of vortioxetine in patients with major depressive disorder comorbid with generalized anxiety disorder: Results of the RECONNECT study
por: Christensen, Michael Cronquist, et al.
Publicado: (2022)

Vortioxetine for Cognitive Enhancement in Major Depression: From Animal Models to Clinical Research
por: Bennabi, Djamila, et al.
Publicado: (2019)

Systematic Review and Meta-Analysis of Vortioxetine for the Treatment of Major Depressive Disorder in Adults
por: Zhang, Xinyan, et al.
Publicado: (2022)

Efficacy of Vortioxetine on Anhedonia: Results from a Pooled Analysis of Short-Term Studies in Patients with Major Depressive Disorder
por: McIntyre, Roger S, et al.
Publicado: (2021)

Differences in Perceptions of Major Depressive Disorder Symptoms and Treatment Priorities Between Patients and Health Care Providers Across the Acute, Post-Acute, and Remission Phases of Depression
por: Baune, Bernhard T., et al.
Publicado: (2019)

Vortioxetine Modulates the Regional Signal in First-Episode Drug-Free Major Depressive Disorder at Rest
por: Xiong, Shihong, et al.
Publicado: (2022)

Vortioxetine Improved Depressive State In Parkinson’s Disease
por: Yoshimura, Reiji, et al.
Publicado: (2021)

Long-term follow-up on health-related quality of life in major depressive disorder: a 2-year European cohort study
por: Saragoussi, Delphine, et al.
Publicado: (2018)

An Interim Analysis of a Randomized, Open-Label Study of Vilazodone, Escitalopram, or Vortioxetine for Major Depressive Disorder
por: Santi, N Simple, et al.
Publicado: (2023)

A Subgroup Analysis of the Impact of Vortioxetine on Functional Capacity, as Measured by UPSA, in Patients with Major Depressive Disorder and Subjective Cognitive Dysfunction
por: Keefe, Richard S E, et al.
Publicado: (2018)

Real-world effectiveness of vortioxetine in outpatients with major depressive disorder: functioning and dose effects
por: Papalexi, Eugenia, et al.
Publicado: (2022)

Symptoms of Major Depressive Disorder and Their Impact on Psychosocial Functioning in the Different Phases of the Disease: Do the Perspectives of Patients and Healthcare Providers Differ?
por: Christensen, Michael Cronquist, et al.
Publicado: (2020)

Punding Behavior as a Red Flag for Dementia in a Patient With Depression: Case Report
por: Pouchon, Arnaud, et al.
Publicado: (2021)

Effectiveness of vortioxetine in patients with major depressive disorder and comorbid Alzheimer’s disease in routine clinical practice: An analysis of a post-marketing surveillance study in South Korea
por: Cumbo, Eduardo, et al.
Publicado: (2023)

Adjunctive vortioxetine for SSRI-resistant major depressive disorder: a “real-world” chart review study
por: De Berardis, Domenico, et al.
Publicado: (2020)

Naturalistic and Uncontrolled Pilot Study on the Efficacy of Vortioxetine in Binge Eating Disorder With Comorbid Depression
por: Segura-Garcia, Cristina, et al.
Publicado: (2021)

Impact of Cognitive Symptoms on Health-Related Quality of Life and Work Productivity in Chinese Patients with Major Depressive Disorder: Results from the PROACT Study
por: Wang, Gang, et al.
Publicado: (2020)

Effectiveness and Safety of Vortioxetine for the Treatment of Major Depressive Disorder in the Real World: A Systematic Review and Meta-Analysis
por: Li, Zejun, et al.
Publicado: (2023)

The impact of dose on the real-world effectiveness of vortioxetine in outpatients with mdd in greece
por: Papalexi, E., et al.
Publicado: (2021)

Pharmacology and clinical potential of vortioxetine in the treatment of major depressive disorder
por: Alvarez, Enric, et al.
Publicado: (2014)

Effects of Vortioxetine on Sleep Architecture of Adolescents with Major Depressive Disorder
por: Mlyncekova, Zuzana, et al.
Publicado: (2023)

A Real-World, Prospective, Multicenter, Single-Arm Observational Study of Duloxetine in Patients With Major Depressive Disorder or Generalized Anxiety Disorder
por: Szekeres, Gyorgy, et al.
Publicado: (2021)

Saccadic Performance and Cortical Excitability as Trait-Markers and State-Markers in Rapid Cycling Bipolar Disorder: A Two-Case Follow-Up Study
por: Malsert, Jennifer, et al.
Publicado: (2013)

Emotional blunting in patients with depression. Part I: clinical characteristics
por: Christensen, Michael Cronquist, et al.
Publicado: (2022)

Investigation of the pharmacological treatment patterns of Chinese patients with major depressive disorder under real-world settings using multi-channel sequence analysis
por: Wu, Tao, et al.
Publicado: (2023)

Emotional blunting in patients with depression. Part III: relationship with psychological trauma
por: Christensen, Michael Cronquist, et al.
Publicado: (2022)

The effect of vortioxetine on overall patient functioning in patients with major depressive disorder
por: Florea, Ioana, et al.
Publicado: (2017)

Major depression with musical obsession treated with vortioxetine: a case report
por: Yoshimura, Reiji, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_nvsirt5dob5247k0cv5m8ekhq6